Loading...
Maven Brands Inc.
TRLFF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.00
$0.00(0.00%)

Over the last four quarters, Maven Brands Inc.'s revenue moved from -$11276.00 in Q4 2022 to $0.00 in Q3 2023. Operating income in Q3 2023 was -$425330.00, with a strong operating margin of N/A. Despite fluctuations in R&D and SG&A expenses, EBITDA for Maven Brands Inc. remained robust at -$233313.00, reflecting operational efficiency. Net income rose to $359780.00, with an EPS of $0.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan